The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer

Journal Article · Wed Sep 18 00:00:00 EDT 2013 · J. Med. Chem.

DOI:https://doi.org/10.1021/jm3005866· OSTI ID:1093491

Lewis, Richard T.; Bode, Christiane M.; Choquette, Deborah M.; Potashman, Michele; Romero, Karina; Stellwagen, John C.; Teffera, Yohannes; Moore, Earl; Whittington, Douglas A.; Chen, Hao; Epstein, Linda F.; Emkey, Renee; Andrews, Paul S.; Yu, Violeta L.; Saffran, Douglas C.; Xu, Man; Drew, Allison; Merkel, Patricia; Szilvassy, Steven; Brake, Rachael L. ^[1]

---

1. Amgen

• Research Organization: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
• Sponsoring Organization: INDUSTRY
• OSTI ID: 1093491
• Journal Information: J. Med. Chem., Vol. 55, Issue (14) ; 07, 2012
• Country of Publication: United States
• Language: ENGLISH